The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...

Think about mental health and the impact of our Invega portfolio, Spravato, and the potential ... providing strategic near- and long-term growth catalysts for Johnson & Johnson.

Presentation Operator Good morning and welcome to Johnson and Johnson's fourth quarter 2024 earnings conference call. All participants will be in listen only mode until the question and answer session ...

John­son & John­son’s bur­geon­ing de­pres­sion treat­ment Spra­va­to eclipsed $1 bil­lion in rev­enue in 2024 as the phar­ma’s neu­ro­science pipeline comes in­to view.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...

From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug ...

nasal spray bottle WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive ...

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced ...